Amid stronger policy support, rapid biomedical innovation, and rising public awareness of health management, healthcare system is accelerating a shift from reactive treatment to proactive, continuous care.
Once a supplementary option, at-home testing is moving to the center of health consumption, bridging clinical reliability with household convenience and giving rise to a fast-growing, household-scale healthcare market in China.
To unlock the new growth momentum for the IVD industry and extend its value boundaries, CACLP 2026 will, for the first time, introduce the At-Home Testing Pavilion, taking place from 21¨C23 March 2026 in Hall 5, Xiamen International Expo Center.
Covering 1,000 sqm, the Pavilion integrates brand showcase, hands-on experience and resource matchmaking, presenting a comprehensive view of at-home testing across household scenarios, platform ecosystems and real consumer journeys.
Policy¡ª¡ª
At-home rapid testing and intelligent health monitoring have been explicitly incorporated into China¡¯s national consumption and healthcare support.
Technology¡ª¡ª
At-home testing is no longer synonymous with low-end solutions, but represents earlier diagnostics, forward-shifted disease management, and continuous monitoring.
Demand¡ª¡ª
Chronic disease management, aging populations and long-term health awareness are driving testing frequency from occasional use to daily routines.
Channel¡ª¡ª
The first touchpoint for family health is moving beyond hospitals toward platform-based networks and home-centered scenarios.
